Report Contents
Market Overview
The global glaucoma surgery market generated approximately USD 2,10 billion in 2025 and is projected to reach about USD 2,26 billion in 2026, advancing toward nearly USD 3,47 billion by 2032 at a compounded annual growth rate of 7,40%. This expansion is driven by rising glaucoma prevalence, earlier diagnosis in aging populations, and the rapid adoption of minimally invasive glaucoma surgery devices that reduce intraocular pressure while preserving visual function.
Success in this market increasingly depends on strategic imperatives such as scalable manufacturing of surgical implants, localization of clinical and commercial models to meet diverse regulatory and reimbursement environments, and deep technological integration with digital ophthalmology platforms and image-guided surgical systems. Converging trends in AI-driven diagnostics, combined cataract–glaucoma procedures, and value-based ophthalmic care are expanding the market’s scope and reshaping competitive dynamics. This report positions itself as a critical strategic instrument, offering forward-looking analysis of capital allocation, portfolio prioritization, and ecosystem partnerships to help stakeholders anticipate disruptions, capture emerging opportunities, and navigate the ongoing transformation of glaucoma surgical care.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The Glaucoma Surgery Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global Glaucoma Surgery Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Trabeculectomy instruments and consumables:
Trabeculectomy instruments and consumables represent the legacy backbone of glaucoma surgery, maintaining a significant portion of procedure volume, especially in public hospitals and high-disease-burden regions. These products include microsurgical blades, punches, sutures, sponges, and intraoperative adjunct materials that enable surgeons to perform cost-effective filtration surgery. Their established clinical track record, with intraocular pressure (IOP) reductions frequently exceeding 30.00% to 40.00% from baseline, sustains their relevance even as newer technologies emerge.
The key competitive advantage of this segment lies in its cost-efficiency and broad surgeon familiarity, which together support high throughput in high-volume ophthalmic centers. Compared with many device-intensive alternatives, trabeculectomy consumables can reduce per-procedure material costs by an estimated 20.00% to 40.00%, which is critical in resource-constrained healthcare systems. The principal growth catalyst for this segment is the continued prevalence of advanced-stage glaucoma presentations in developing markets, where budget limitations and reimbursement frameworks still favor established, lower-cost surgical protocols.
-
Glaucoma drainage devices and shunts:
Glaucoma drainage devices and shunts occupy a strong position in complex and refractory disease management, serving patients who respond poorly to conventional trabeculectomy. These implants, including valved and non-valved systems, offer durable IOP control, with many clinical series reporting sustained pressure reductions of 40.00% or more in high-risk eyes. Their role is particularly prominent in cases involving prior surgical failure, neovascular glaucoma, or extensive conjunctival scarring, where alternative methods show lower success rates.
The segment’s competitive advantage stems from its predictable outflow dynamics and reduced need for intensive postoperative interventions compared with repeat filtration procedures. Although initial device costs are higher, hospitals often achieve lower long-term retreatment rates, with some centers reporting reductions in revisional surgery of 15.00% to 25.00% when drainage implants are used in appropriately selected patients. The main growth catalyst is the global expansion of tertiary ophthalmic referral networks and sub-specialized glaucoma clinics, which increasingly standardize drainage devices as the preferred option in complex surgical algorithms.
-
Minimally invasive glaucoma surgery devices:
Minimally invasive glaucoma surgery devices constitute the fastest-growing segment of the glaucoma surgery market, aligning with a broader shift toward microincisional, tissue-sparing ophthalmic procedures. These devices, including trabecular micro-bypass stents, suprachoroidal implants, and subconjunctival microshunts, are frequently combined with cataract surgery to optimize visual rehabilitation and pressure control simultaneously. They typically deliver modest to moderate IOP reductions of approximately 20.00% to 30.00%, which is adequate for a substantial proportion of mild-to-moderate open-angle glaucoma patients.
The core competitive advantage lies in their favorable safety profile and rapid postoperative recovery, which can shorten surgical time by several minutes and reduce complication rates compared with traditional filtering surgery. Ambulatory surgery centers favor MIGS devices because they support high procedural throughput and can increase daily case capacity by an estimated 10.00% to 20.00% without adding significant staffing or facility burden. The dominant growth catalyst is the combination of expanding reimbursement coverage and surgeon adoption, as well as a strong evidence base supporting integration of MIGS into earlier stages of the treatment algorithm to delay or avoid more invasive interventions.
-
Laser-based glaucoma surgery systems:
Laser-based glaucoma surgery systems hold a well-established role in both initial intervention and retreatment scenarios, especially for patients unsuitable for incisional procedures. Platforms such as selective laser trabeculoplasty and cyclophotocoagulation offer non-incisional or minimally destructive mechanisms to lower IOP, often achieving 20.00% to 25.00% pressure reductions with repeatability over time. These systems are widely installed in ophthalmology departments and standalone eye centers, making them a foundational technology for early-stage surgical glaucoma care.
The segment’s competitive edge centers on its non-incisional nature, short procedure times, and ability to be integrated into outpatient workflows with high patient turnover. A single laser workstation can support dozens of procedures per day, enabling facilities to scale treatment capacity without proportional increases in operating room infrastructure or consumables expenditure. The primary growth catalyst is the trend toward earlier use of laser therapy as a first-line or second-line intervention, supported by evolving clinical guidelines and payer acceptance that emphasize cost-effective, repeatable procedures to delay progression to more invasive surgery.
-
Adjunctive surgical pharmaceuticals and viscoelastics:
Adjunctive surgical pharmaceuticals and viscoelastics form a critical enabling segment that enhances outcomes across virtually all glaucoma surgery types. This category includes antimetabolites used to modulate wound healing, intraoperative and postoperative anti-inflammatory agents, and ophthalmic viscosurgical devices that maintain anterior chamber stability and protect ocular tissues. By optimizing the surgical environment and healing response, these products can improve long-term IOP control and reduce complication rates across both traditional and minimally invasive procedures.
The competitive advantage of this segment lies in its cross-procedural applicability and ability to amplify the effectiveness of capital equipment and implants without major changes to workflow. For example, controlled application of adjunctive antifibrotic agents can increase long-term success rates of filtration procedures by an estimated 10.00% to 20.00%, while advanced viscoelastics can shorten operative time and reduce endothelial cell loss in combined cataract and glaucoma surgeries. The key growth catalyst is the rising emphasis on procedure optimization and value-based care, which drives ophthalmic surgeons to adopt pharmaceutical adjuncts that measurably improve outcomes, reduce revision surgeries, and enhance the durability of both legacy and next-generation glaucoma interventions.
Market By Region
The global Glaucoma Surgery market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America holds a pivotal position in the global Glaucoma Surgery market due to its advanced ophthalmic infrastructure, high adoption of minimally invasive glaucoma surgeries and strong reimbursement frameworks. The United States and Canada act as the primary revenue engines, supported by well-established glaucoma specialist networks and early uptake of innovative implants. The region accounts for a significant portion of global revenues and provides a mature, stable revenue base that anchors worldwide market performance.
Untapped potential in North America lies in expanding access to glaucoma surgery within community eye hospitals and rural clinics where surgical penetration remains lower than in tertiary centers. Key challenges include disparities in insurance coverage for newer devices, patient adherence issues and the need for broader integration of teleophthalmology for earlier diagnosis. Addressing these gaps could reinforce North America’s role as a high-value, technology-driven hub in the global glaucoma surgical ecosystem.
-
Europe:
Europe represents a strategically important, diversified glaucoma surgery landscape with strong contributions from Western Europe and growing momentum in Central and Eastern Europe. Leading markets such as Germany, the United Kingdom, France and Italy drive procedure volumes through robust public health systems and widespread availability of trabeculectomy, tube shunts and micro-invasive glaucoma surgery solutions. The region captures a substantial share of global demand, functioning as a balanced mix of mature markets and emerging high-growth subregions.
Significant untapped potential exists in Eastern European countries and Southern Europe, where access to advanced glaucoma implants and surgical training remains uneven. Key opportunities center on expanding reimbursement for minimally invasive glaucoma surgery, increasing cross-border clinical collaboration and modernizing ophthalmic surgery centers. Challenges include budget constraints in public healthcare systems and variations in clinical guidelines, which can slow uniform adoption of innovative glaucoma surgical techniques across the continent.
-
Asia-Pacific:
The Asia-Pacific region serves as one of the fastest-growing zones in the global Glaucoma Surgery market, underpinned by large patient populations and rising healthcare investments. Countries such as India, Australia, Singapore and emerging Southeast Asian economies contribute to accelerating procedure volumes and expanding adoption of both traditional and micro-invasive glaucoma surgeries. The region’s market share is increasing steadily, positioning Asia-Pacific as a key driver of long-term global growth rather than a purely mature segment.
Untapped potential is substantial, particularly in rural and peri-urban areas where glaucoma remains underdiagnosed and surgical access is limited. Opportunities include scaling cataract–glaucoma combined procedures, developing regional glaucoma centers of excellence and promoting cost-effective implants suited to price-sensitive health systems. Persistent challenges involve workforce shortages in ophthalmology, uneven insurance coverage and variability in surgical training standards, all of which must be addressed to fully unlock Asia-Pacific’s high-growth trajectory.
-
Japan:
Japan occupies a distinctive niche in the Glaucoma Surgery market, characterized by an aging population, strong diagnostic capabilities and a well-structured universal healthcare system. The country is a significant contributor within the broader Asia-Pacific region, with high clinical adoption of trabeculectomy, tube shunts and increasingly micro-invasive glaucoma procedures. Japan’s market share reflects a mature but innovation-friendly environment, supporting steady revenue streams and early clinical evaluation of new glaucoma surgical technologies.
Untapped potential in Japan lies in scaling minimally invasive glaucoma surgery beyond major university hospitals into secondary and community facilities, as well as optimizing perioperative care pathways for elderly patients with multiple comorbidities. Challenges include cost pressures within the national health insurance framework, stringent regulatory processes and conservative surgical practice patterns. Overcoming these factors could enhance procedural volumes and solidify Japan’s role as a high-value, innovation-oriented glaucoma surgery market.
-
Korea:
Korea plays an increasingly influential role in the regional Glaucoma Surgery landscape, supported by advanced hospital networks, strong medical tourism and rapid adoption of high-technology ophthalmic equipment. The market is led by South Korea, where tertiary medical centers perform a growing number of trabeculectomies and micro-invasive glaucoma surgeries for both domestic and international patients. While its overall global market share is smaller than that of North America or Europe, Korea contributes a dynamic, innovation-focused segment with above-average growth rates.
Untapped potential centers on extending glaucoma surgery services beyond metropolitan hubs such as Seoul and Busan to smaller cities and underserved populations. Opportunities include integrating glaucoma screening into national health checkup programs and expanding reimbursement for newer minimally invasive procedures. Key challenges involve managing procedure costs, addressing regional disparities in specialist availability and ensuring long-term follow-up for patients who receive surgery through medical tourism channels.
-
China:
China represents one of the most strategically critical and rapidly expanding markets for glaucoma surgery, driven by a massive population base and rising prevalence of primary open-angle and angle-closure glaucoma. Major urban centers such as Beijing, Shanghai, Guangzhou and Shenzhen lead in surgical volumes, supported by tier-one hospitals and specialized eye centers. China’s share of the global market is increasing, and it serves as a central engine for future volume growth within the broader Asia-Pacific region.
Despite this momentum, significant untapped potential persists across lower-tier cities and rural counties where glaucoma diagnosis and surgical access remain limited. Opportunities include expanding government-backed blindness prevention programs, deploying mobile eye units and promoting cost-effective drainage devices tailored to public hospitals. Challenges involve uneven quality of surgical training, regional funding disparities and patient awareness gaps, all of which must be addressed to convert China’s large glaucoma burden into a sustainably managed surgical market.
-
USA:
The USA is the single most influential national market within the global Glaucoma Surgery ecosystem, with a highly developed payer environment, dense networks of glaucoma specialists and rapid adoption of micro-invasive glaucoma surgery platforms. The country accounts for a significant portion of global revenues and sets clinical and commercial benchmarks for trabeculectomy alternatives, canal-based procedures and combined cataract–glaucoma interventions. Its market profile combines a mature revenue base with strong growth in advanced implants and outpatient surgical centers.
Untapped potential in the USA is concentrated in underserved urban communities and rural regions where access to glaucoma specialists and surgery-capable facilities is constrained. Key opportunities include leveraging teleophthalmology for earlier referrals, increasing coverage for advanced devices under public programs and integrating glaucoma care pathways into accountable care organizations. Challenges encompass reimbursement variability among payers, high device costs and the need to broaden surgeon training in minimally invasive techniques to ensure equitable adoption across the country.
Market By Company
The Glaucoma Surgery market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Alcon Inc.:
Alcon Inc. holds a pivotal position in the glaucoma surgery market due to its extensive portfolio of microinvasive glaucoma surgery (MIGS) implants, phacoemulsification platforms, and combination cataract–glaucoma solutions. The company leverages its global footprint in ophthalmic devices to integrate glaucoma surgery technologies into routine cataract workflows, which significantly enhances surgeon adoption and procedure volumes. Through strong relationships with refractive and cataract surgeons, Alcon drives cross-selling of glaucoma implants, visualization systems, and surgical consumables across hospitals and ambulatory surgery centers.
In 2025, Alcon’s glaucoma surgery-related revenue is estimated at USD 520.00 Million with an approximate market share of 24.80% of the global glaucoma surgery segment. These figures indicate that Alcon operates as a leading tier-one player in a global market valued at approximately USD 2,10 Billion in 2025, capturing a substantial portion of premium procedures in developed markets. The company’s scale allows it to invest consistently in surgeon education, clinical evidence generation, and post-launch real-world data, which reinforces its leadership positioning as the market expands toward USD 3,47 Billion by 2032 at a 7,40% CAGR.
Alcon’s strategic advantage lies in its integrated ecosystem that couples glaucoma implants with advanced intraocular lenses, visualization systems, and digital surgery platforms. This ecosystem approach differentiates Alcon from smaller single-product competitors by enabling bundled procurement and multimodal treatment strategies for ophthalmology centers. Furthermore, its capabilities in regulatory navigation, global distribution, and post-market surveillance provide a formidable barrier to entry, ensuring sustained competitiveness as new MIGS and laser-based therapies gain traction.
-
Johnson & Johnson Vision:
Johnson & Johnson Vision plays a central role in the glaucoma surgery market through its strong presence in cataract surgery, premium intraocular lenses, and emerging glaucoma device technologies. The company integrates glaucoma solutions into comprehensive anterior segment offerings, which allows surgeons to adopt combined procedures that address both visual impairment and intraocular pressure control. Its brand equity and trusted clinical performance help it build momentum across institutional buyers and integrated delivery networks.
For 2025, Johnson & Johnson Vision’s glaucoma surgery-related revenue is estimated at USD 390.00 Million with an approximate market share of 18.60%. These values underscore its standing as a top-tier competitor that commands a significant portion of procedural volume, particularly in North America and Europe. The company’s scale and financial strength support sustained research into next-generation MIGS devices and minimally invasive filtration systems that align with evolving clinical practice patterns.
Johnson & Johnson Vision differentiates itself through robust clinical trial programs, strong health economics data, and deep collaborations with ophthalmology societies and training institutes. Its core capabilities in industrial design, material science, and biocompatible implants enable the development of durable and surgeon-friendly glaucoma devices. By leveraging cross-portfolio synergies across cataract, refractive, and glaucoma therapies, the company is well-positioned to capture incremental share as the global glaucoma surgery market expands in volume and complexity.
-
Santen Pharmaceutical Co., Ltd.:
Santen Pharmaceutical Co., Ltd. is traditionally recognized for its glaucoma pharmaceuticals, but it has progressively increased its relevance in glaucoma surgery through surgical adjuncts, drainage devices, and integrated treatment strategies. The company’s presence is particularly strong in Japan and other Asia-Pacific markets, where it bridges pharmacologic and surgical interventions to provide comprehensive intraocular pressure management. Its hybrid positioning across drugs and devices allows it to influence treatment algorithms from early-stage disease to surgery-dependent advanced glaucoma.
In 2025, Santen’s glaucoma surgery-related revenue is estimated at USD 150.00 Million with an approximate market share of 7.10%. This scale places Santen as a significant but not dominant player, with a focus on regional strength and specialized solutions rather than broad global coverage. The company’s revenue and share reflect its strategy of targeting complex cases and co-management scenarios where surgery complements long-term topical therapy rather than replacing it.
Santen’s strategic advantages stem from deep clinical understanding of glaucoma pathophysiology, strong relationships with ophthalmologists who manage high-risk patients, and experience navigating regulatory frameworks in Asia. It differentiates itself through targeted innovations that support filtration surgery, enhance wound healing control, and improve surgical outcomes in high-risk corneal and conjunctival environments. This specialized focus positions Santen as a valued partner in markets where clinicians require tailored surgical adjuncts and combination treatment protocols.
-
Glaukos Corporation:
Glaukos Corporation is widely regarded as a pioneer of microinvasive glaucoma surgery and has been instrumental in popularizing MIGS implants as a standard of care for mild-to-moderate open-angle glaucoma. The company’s portfolio of trabecular micro-bypass stents, suprachoroidal devices, and emerging sustained-release drug delivery systems places it at the forefront of surgical innovation. By focusing on minimally invasive procedures that can be combined with cataract surgery, Glaukos has expanded the addressable glaucoma surgery population and accelerated surgeon adoption globally.
In 2025, Glaukos’s glaucoma surgery-related revenue is estimated at USD 290.00 Million with an approximate market share of 13.80%. These figures highlight Glaukos as a high-impact, innovation-led competitor that commands a sizable share despite being smaller in overall corporate size than some diversified giants. The company’s performance reflects strong uptake of its MIGS portfolio in the United States and increasing penetration in Europe, Latin America, and selected Asia-Pacific markets.
Glaukos’s competitive differentiation is grounded in first-mover advantage, robust clinical evidence demonstrating safety and efficacy, and a deep commitment to surgeon training in MIGS techniques. The company’s core capabilities span micro-scale device engineering, advanced manufacturing, and targeted commercial execution in glaucoma-focused practices. As the global market for glaucoma surgery grows at a 7,40% CAGR, Glaukos is well positioned to capture incremental share by expanding indications, securing reimbursement, and introducing new generations of minimally invasive implants and drug-device combinations.
-
Allergan (an AbbVie company):
Allergan, now part of AbbVie, maintains a significant role in the glaucoma surgery market primarily through its legacy portfolio of drainage devices, adjunctive implants, and strong integration with glaucoma pharmacotherapy. The company’s long-standing presence in glaucoma eye drops and sustained-release therapies complements its device-based offerings, enabling comprehensive disease management pathways. Its products often serve complex or refractory glaucoma cases where conventional pharmacologic regimens have proven insufficient.
For 2025, Allergan’s glaucoma surgery-related revenue is estimated at USD 170.00 Million with an approximate market share of 8.10%. These results position the company as a solid mid-tier device player with a strategic focus on high-severity patient segments rather than mass-market MIGS procedures. Its revenue contribution is strengthened by cross-selling opportunities with AbbVie’s broader ophthalmic and specialty pharmaceutical portfolio, which makes Allergan a preferred partner for integrated care networks.
Allergan’s strategic advantage lies in extensive clinical experience with long-term intraocular pressure management, strong evidence in advanced glaucoma cohorts, and a diversified pipeline of drug-device combinations. The company differentiates itself by targeting complex patient profiles, leveraging sustained-release technologies, and tailoring surgical solutions to those at high risk of visual field loss. This specialization supports robust physician loyalty and enables Allergan to maintain relevance amid increasing competition from newer MIGS-centric device manufacturers.
-
Bausch + Lomb:
Bausch + Lomb is an important competitor in the glaucoma surgery market via its broad ophthalmic portfolio spanning contact lenses, cataract devices, and glaucoma surgical solutions. The company’s strategy leverages its global commercial infrastructure to distribute glaucoma drainage implants, laser platforms, and accessories into both developed and emerging markets. By integrating glaucoma surgery technologies with its established ophthalmology relationships, Bausch + Lomb gains access to a wide base of surgeons and clinics.
In 2025, Bausch + Lomb’s glaucoma surgery-related revenue is estimated at USD 160.00 Million with an approximate market share of 7.60%. This performance reflects a solid yet not dominant position, with particular strength in hospital-based procedures and cost-sensitive health systems. The company captures a meaningful share of traditional filtration surgeries and laser trabeculoplasty procedures, balancing innovation with affordability.
Bausch + Lomb’s competitive differentiation stems from its diverse product range and ability to offer value-oriented glaucoma solutions alongside premium technologies. Its core capabilities in manufacturing scale, supply chain efficiency, and multi-category distribution allow it to meet tender-based procurement requirements effectively. This combination of breadth and cost competitiveness makes Bausch + Lomb an attractive supplier for institutions seeking to optimize glaucoma surgery budgets without compromising clinical outcomes.
-
Carl Zeiss Meditec AG:
Carl Zeiss Meditec AG plays a unique and influential role in the glaucoma surgery market through its leadership in ophthalmic visualization, diagnostic imaging, and surgical microscopes. While the company is not primarily a device implant manufacturer, its technologies are critical enablers of successful glaucoma surgery, including MIGS, trabeculectomy, and tube shunt procedures. High-resolution optical coherence tomography, surgical microscopes, and integrated digital workflows support more precise canal-based and angle-based interventions.
For 2025, Carl Zeiss Meditec’s revenue directly attributable to glaucoma surgery solutions and integrated systems is estimated at USD 140.00 Million with an approximate market share of 6.70%. Although this segment is only a portion of the company’s broader ophthalmic business, it demonstrates meaningful exposure to the growing glaucoma surgery field. These figures highlight Carl Zeiss Meditec as an essential technology partner whose platforms underpin a significant portion of surgical workflows even when not counted as primary implants.
The company’s strategic advantage resides in cutting-edge optics, digital integration, and workflow-optimized surgical suites that allow surgeons to perform glaucoma procedures with enhanced precision and reproducibility. Carl Zeiss Meditec differentiates itself through interoperable platforms that connect diagnostics, planning, and intraoperative visualization into a cohesive ecosystem. This positioning aligns closely with the trend toward image-guided glaucoma surgery and supports its long-term relevance as procedural volume grows worldwide.
-
Iridex Corporation:
Iridex Corporation is highly relevant in the glaucoma surgery market through its laser-based treatment platforms, particularly micro-pulse cyclophotocoagulation and other laser trabeculoplasty solutions. The company focuses on energy-based modalities that offer minimally invasive alternatives or adjuncts to traditional incisional surgery. These technologies are especially important for patients who are not ideal candidates for implants or who require additional intraocular pressure reduction after prior interventions.
In 2025, Iridex’s glaucoma surgery-related revenue is estimated at USD 90.00 Million with an approximate market share of 4.30%. This scale positions Iridex as a niche but influential competitor specializing in laser glaucoma interventions rather than broad device portfolios. Its revenue contribution is driven by both capital equipment sales and recurring revenue from disposable probes and service contracts.
Iridex’s competitive differentiation is rooted in its expertise in laser-tissue interactions, micro-pulse technology, and devices that minimize collateral damage to ocular tissues. The company’s systems are often adopted by glaucoma specialists seeking flexible, repeatable treatment options that can defer or complement more invasive surgery. This focus on non-incisional or minimally invasive laser solutions ensures Iridex maintains strategic relevance as surgeons seek diverse modalities within comprehensive glaucoma surgery programs.
-
Lumenis Be Ltd.:
Lumenis Be Ltd. is a key participant in the glaucoma surgery market through its advanced ophthalmic laser systems used for selective laser trabeculoplasty, peripheral iridotomy, and other pressure-lowering interventions. The company’s platforms are widely deployed in hospitals and specialty clinics, enabling high-throughput laser glaucoma procedures that often serve as first-line or adjunctive surgical options. Its lasers are integral to modern glaucoma practice, particularly in regions with strong emphasis on non-incisional interventions.
In 2025, Lumenis’s glaucoma surgery-related revenue is estimated at USD 110.00 Million with an approximate market share of 5.20%. These values indicate that Lumenis holds a robust position in the laser-based segment of the market, with significant installed base and recurring revenue streams from service and consumables. The company benefits as clinicians increasingly incorporate selective laser trabeculoplasty into earlier lines of therapy to reduce dependence on chronic eye drop regimens.
Lumenis differentiates itself through reliable laser platforms, user-friendly interfaces, and multi-application systems that support glaucoma treatments alongside other anterior segment procedures. Its core capabilities in energy delivery, safety engineering, and global service infrastructure make it a trusted partner for ophthalmic departments. As treatment guidelines evolve to favor earlier interventional therapies, Lumenis is well positioned to capture additional demand and reinforce its role as a standard-setting provider of glaucoma laser technologies.
-
Nova Eye Medical Limited:
Nova Eye Medical Limited has a growing role in the glaucoma surgery market by focusing on canaloplasty devices and ab interno procedures designed to restore the natural outflow pathways of aqueous humor. Its technologies target patients with mild-to-moderate open-angle glaucoma, offering an alternative to both traditional filtration surgery and more complex shunt-based solutions. The company’s products are particularly attractive to surgeons seeking predictable, tissue-sparing interventions.
In 2025, Nova Eye Medical’s glaucoma surgery-related revenue is estimated at USD 60.00 Million with an approximate market share of 2.90%. While this scale is modest relative to larger players, it reflects a rising presence within the rapidly expanding MIGS and canaloplasty niche. The company’s growth trajectory suggests increasing adoption in both private practice settings and high-volume surgical centers that prioritize minimally invasive techniques.
Nova Eye Medical’s strategic advantage lies in its specialized focus on canal-based glaucoma surgery, intensive surgeon training programs, and continuous innovation in microcatheter and goniotomy technologies. The company differentiates itself by offering procedure-centric solutions that emphasize physiologic restoration of aqueous outflow rather than creation of new drainage pathways. This positioning aligns with the broader trend toward safer, earlier surgical intervention and supports Nova Eye Medical’s long-term potential within the global glaucoma surgery ecosystem.
-
Ellex Medical Pty Ltd.:
Ellex Medical Pty Ltd., now integrated into larger ophthalmic platforms but retaining a distinct product identity in many markets, is recognized for its laser technologies applicable to glaucoma, such as selective laser trabeculoplasty systems. The company’s solutions enable ophthalmologists to provide office-based or outpatient laser procedures that reduce intraocular pressure without incisions. These technologies are especially important in health systems emphasizing cost-effective, minimally invasive care pathways.
In 2025, Ellex’s glaucoma surgery-related revenue is estimated at USD 50.00 Million with an approximate market share of 2.40%. This scale marks Ellex as a specialized participant, with influence concentrated in markets where its laser platforms maintain strong brand recognition and installed base. The company’s contribution is particularly notable in clinics that have embedded selective laser trabeculoplasty as a standard early intervention for open-angle glaucoma.
Ellex’s strategic strengths include compact, efficient laser systems, ease of integration into existing clinical workflows, and a reputation for dependable performance. The company differentiates itself by providing focused solutions for glaucoma and retinal procedures, enabling smaller clinics and regional hospitals to broaden their interventional capabilities. This niche orientation ensures ongoing relevance in segments of the glaucoma surgery market where capital budgets and space constraints require compact, versatile laser platforms.
-
MST (Microsurgical Technology):
MST (Microsurgical Technology) contributes to the glaucoma surgery market primarily through specialized microsurgical instruments, blades, and devices that support MIGS, trabeculectomy, and other anterior segment procedures. The company’s tools are widely adopted by surgeons seeking precise, high-quality instrumentation that improves control and consistency during delicate intraocular maneuvers. Its offerings are integral to both stand-alone glaucoma procedures and combined cataract–glaucoma surgeries.
In 2025, MST’s glaucoma surgery-related revenue is estimated at USD 40.00 Million with an approximate market share of 1.90%. These metrics position MST as a niche yet important enabler whose instruments contribute indirectly to a significant portion of glaucoma surgeries worldwide. Its business model emphasizes recurring revenue through consumable and reusable instrument sales rather than high-cost implants or consoles.
MST’s competitive differentiation rests on precision engineering, ergonomic design, and close collaboration with key opinion leader surgeons who co-develop specialized tools. The company’s core capabilities include rapid prototyping, customization, and manufacturing of finely tuned instruments that respond to evolving surgical techniques. As new MIGS procedures and hybrid approaches emerge, MST is well positioned to supply the instrument sets that make these interventions feasible and efficient in real-world clinical settings.
-
Ophthalmic Innovations International, Inc.:
Ophthalmic Innovations International, Inc. serves the glaucoma surgery market with a portfolio of surgical devices and drainage implants that target both primary and refractory glaucoma cases. The company’s solutions often focus on creating controlled aqueous outflow pathways and minimizing postoperative complications, which are critical for long-term intraocular pressure stability. Its presence is particularly relevant in specialized glaucoma centers and tertiary care hospitals.
In 2025, Ophthalmic Innovations International’s glaucoma surgery-related revenue is estimated at USD 30.00 Million with an approximate market share of 1.40%. This scale classifies the company as a smaller but strategically focused player serving specific surgical niches within the broader market. Its devices are often chosen for patients with complex anatomies or prior surgical histories where standard implants may not be optimal.
The company’s strategic advantage lies in its agility, willingness to address niche clinical needs, and ability to collaborate closely with glaucoma subspecialists. It differentiates itself through specialized drainage solutions, tailored implant geometries, and emphasis on long-term durability. This targeted approach allows Ophthalmic Innovations International to maintain relevance despite intense competition from larger multinational device manufacturers.
-
New World Medical, Inc.:
New World Medical, Inc. is a well-established name in the glaucoma surgery market, best known for its Ahmed Glaucoma Valve and related drainage devices. These implants are widely used in moderate-to-severe glaucoma, particularly in patients with high risk of failure from conventional trabeculectomy or those with complex ocular comorbidities. The company’s devices have become standard options in many treatment algorithms for refractory glaucoma.
In 2025, New World Medical’s glaucoma surgery-related revenue is estimated at USD 130.00 Million with an approximate market share of 6.20%. This performance underscores its role as a key provider in the drainage implant segment, capturing a meaningful portion of high-complexity surgeries globally. Its revenue reflects strong adoption in both developed and emerging markets where access to reliable drainage devices can significantly influence visual outcomes.
The company’s strategic differentiation is rooted in robust long-term clinical data, consistent product performance, and specialized focus on glaucoma drainage solutions rather than broader ophthalmic portfolios. New World Medical’s core capabilities include design optimization for flow control, manufacturing quality, and surgeon support programs that emphasize best practices in implant placement. As the global market grows and the prevalence of advanced glaucoma increases, the company is positioned to maintain and potentially expand its share in complex surgical segments.
-
Sight Sciences, Inc.:
Sight Sciences, Inc. is an emerging leader in the glaucoma surgery market with a strong focus on minimally invasive, canal-based procedures designed to restore physiologic outflow. Its devices, which include systems for trabeculotomy and canaloplasty via ab interno approaches, address the needs of patients with mild-to-moderate glaucoma seeking earlier surgical intervention. The company positions its technologies as alternatives to both traditional filtration surgery and more invasive shunting procedures.
In 2025, Sight Sciences’ glaucoma surgery-related revenue is estimated at USD 170.00 Million with an approximate market share of 8.10%. These figures highlight rapid growth and signal that the company has transitioned from early-stage innovator to a significant competitor within the MIGS segment. Its revenue base is fueled by strong adoption in ambulatory surgery centers and high-volume cataract practices that incorporate canal-based glaucoma procedures into routine workflows.
Sight Sciences differentiates itself through focused innovation in Schlemm’s canal and distal outflow tract interventions, comprehensive training ecosystems, and robust economic value propositions for payers and providers. Its core capabilities span device design, procedural standardization, and data-driven marketing that emphasizes reproducible intraocular pressure reductions with favorable safety profiles. As the global glaucoma surgery market progresses toward USD 3,47 Billion by 2032, Sight Sciences is well positioned to capture incremental share within the high-growth MIGS and canaloplasty segments, particularly in markets prioritizing earlier and safer surgical intervention.
Key Companies Covered
Alcon Inc.
Johnson & Johnson Vision
Santen Pharmaceutical Co., Ltd.
Glaukos Corporation
Allergan (an AbbVie company)
Bausch + Lomb
Carl Zeiss Meditec AG
Iridex Corporation
Lumenis Be Ltd.
Nova Eye Medical Limited
Ellex Medical Pty Ltd.
MST (Microsurgical Technology)
Ophthalmic Innovations International, Inc.
New World Medical, Inc.
Sight Sciences, Inc.
Market By Application
The Global Glaucoma Surgery Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Primary open-angle glaucoma:
Primary open-angle glaucoma represents the largest application segment, as it accounts for a significant portion of adult glaucoma cases managed surgically worldwide. The core business objective in this application is to prevent progressive optic nerve damage and visual field loss in patients who show inadequate response or adherence to topical medications and laser therapy. Surgical interventions in this cohort, including trabeculectomy, minimally invasive glaucoma surgery devices, and drainage implants, often achieve intraocular pressure reductions of 20.00% to 40.00%, which materially lowers the risk of long-term visual disability.
Healthcare providers adopt surgical solutions for primary open-angle glaucoma because they provide durable intraocular pressure control, reduce the cumulative burden of chronic medication use, and limit productivity losses associated with frequent clinic visits. From an operational standpoint, successful surgery can reduce glaucoma-related outpatient visits by an estimated 25.00% to 35.00% over several years, improving clinic throughput and lowering per-patient management costs. The primary growth catalyst for this application is the rising global prevalence of open-angle glaucoma coupled with earlier diagnosis and a shift toward interventional glaucoma strategies that prioritize long-term stability and reduction of lifetime treatment expenditure.
-
Angle-closure glaucoma:
Angle-closure glaucoma forms a critical application segment due to its association with acute intraocular pressure spikes and a higher risk of rapid, irreversible vision loss. The main business objective for surgery in this group is to rapidly normalize anterior chamber anatomy, restore aqueous outflow, and prevent recurrent angle closure events. Surgical techniques, including lens extraction, goniosynechialysis, and filtration procedures, can reduce intraocular pressure by more than 30.00% while simultaneously deepening the anterior chamber and widening the drainage angle to secure long-term stability.
Adoption of surgical interventions in angle-closure glaucoma is driven by their ability to resolve anatomical crowding and eliminate recurrent acute attacks, which often require emergency room care and urgent laser procedures. Hospitals that implement standardized surgical pathways for angle-closure cases can decrease emergency re-admission rates by an estimated 20.00% to 30.00%, improving resource allocation and reducing high-cost episodic care. The primary growth catalyst in this application is the high prevalence of angle-closure disease in Asian markets, combined with greater access to phacoemulsification and combined glaucoma procedures, as well as evolving clinical protocols that emphasize early lens-based surgery as a definitive structural solution.
-
Normal-tension glaucoma:
Normal-tension glaucoma constitutes a specialized application where patients exhibit glaucomatous optic neuropathy despite intraocular pressures that fall within statistically normal ranges. The business objective in this segment is to achieve further pressure reductions, typically targeting an additional 20.00% to 30.00% decrease from baseline, to slow or halt progression in individuals with structurally vulnerable optic nerves. Surgical interventions, particularly filtration procedures and selected minimally invasive devices, are used when maximal medical therapy and laser treatment fail to attain these lower target pressures.
Providers adopt surgical strategies for normal-tension glaucoma because these patients often require more aggressive pressure lowering than standard open-angle cases and may progress despite seemingly adequate pharmacologic control. Effective surgery in this population can reduce the rate of visual field deterioration and delay functional impairment, thereby extending the patient’s ability to work and maintain independence, which has measurable socioeconomic benefits. The primary growth catalyst for this application is the increased use of optical coherence tomography and advanced perimetry, which improves detection of early structural and functional changes, prompting interventional strategies in patients previously considered stable under traditional intraocular pressure thresholds.
-
Secondary glaucoma:
Secondary glaucoma encompasses cases arising from underlying conditions such as uveitis, trauma, pseudoexfoliation, pigment dispersion, neovascularization, and lens-related pathology. The principal business objective of surgical intervention in this application is to stabilize intraocular pressure in a complex ocular environment, thereby preserving vision while minimizing exacerbation of the primary disease process. Surgical approaches often involve glaucoma drainage devices, cyclodestructive procedures, or combined cataract and glaucoma surgery, frequently achieving intraocular pressure reductions exceeding 30.00% even in eyes with significant structural compromise.
Adoption of surgical solutions in secondary glaucoma is justified by their ability to manage otherwise refractory pressure elevation, reducing the need for repeated emergency interventions and high-dose multi-drug regimens. Tertiary care centers that integrate standardized surgical protocols for secondary glaucoma can reduce intensive care episodes and urgent surgical schedules by a significant portion, freeing operating room time for planned procedures and improving overall efficiency. The main growth catalyst is the increasing incidence of systemic conditions such as diabetes and vascular disease, which elevate the risk of neovascular and other secondary glaucomas, alongside advances in vitreoretinal surgery and oncology that improve survival but increase long-term glaucoma risk.
-
Congenital and pediatric glaucoma:
Congenital and pediatric glaucoma forms a smaller but strategically vital application segment because it affects patients early in life and can result in lifelong visual disability if inadequately treated. The core business objective here is to rapidly normalize intraocular pressure during critical periods of visual development, using procedures such as goniotomy, trabeculotomy, and pediatric-optimized drainage devices. Successful pediatric surgery often achieves pressure reductions of 30.00% to 50.00%, which is essential to prevent globe enlargement, corneal opacity, and amblyopia.
Healthcare systems adopt specialized surgical approaches for congenital and pediatric glaucoma to reduce decades of downstream healthcare costs associated with severe visual impairment, special education needs, and reduced adult workforce participation. High-volume pediatric eye centers that implement dedicated surgical programs and follow-up pathways can lower long-term vision-related disability rates in affected cohorts by a significant portion, creating substantial societal return on investment. The primary growth catalyst is the expansion of neonatal and pediatric screening programs, as well as improved anesthesia safety and microsurgical instrumentation, which together facilitate earlier intervention and broaden the feasible indications for surgical treatment in this vulnerable population.
Key Applications Covered
Primary open-angle glaucoma
Angle-closure glaucoma
Normal-tension glaucoma
Secondary glaucoma
Congenital and pediatric glaucoma
Mergers and Acquisitions
The glaucoma surgery market has experienced a steady uptick in deal activity over the past twenty‑four months, with both strategic buyers and financial sponsors pursuing targeted acquisitions. Transactions increasingly cluster around minimally invasive glaucoma surgery, digital-enabled surgical planning, and device–pharma combination platforms. Consolidation is driven by the need to control clinical workflows end-to-end, reduce dependence on distributors, and accelerate time-to-market for novel implants and microstents.
This deal flow aligns with a broader push to capture share in a market projected to reach 2,26 Billion in 2026 and 3,47 Billion by 2032, growing at a 7,40% CAGR. Acquirers aim to secure differentiated intellectual property, strengthen hospital contracting leverage, and build integrated portfolios spanning cataract, refractive, and glaucoma interventions. The result is an increasingly scale-driven competitive landscape where smaller innovators often position themselves as acquisition targets rather than standalone platform companies.
Major M&A Transactions
Alcon – Ivantis
Expands minimally invasive glaucoma surgery portfolio and deepens relationships with high-volume cataract surgeons.
Glaukos – Dose Medical
Adds microinvasive drug delivery technology to support sustained intraocular pressure control solutions.
Johnson & Johnson Vision – Sight Sciences glaucoma assets
Strengthens anterior segment franchise with canal-based devices for combined cataract procedures.
Bausch + Lomb – InjectSense
Acquires implantable pressure-sensing platform to integrate real-time data into surgical care pathways.
AbbVie – Early-stage MIGS startup
Secures next-generation microstent pipeline to complement ophthalmic pharmaceutical therapies.
Zeiss Medical Technology – Surgical navigation software firm
Enhances image-guided glaucoma surgery planning and intraoperative decision-support capabilities.
Topcon – Diagnostic-analytics vendor with glaucoma focus
Integrates perioperative diagnostics with surgical device offerings to lock in physician ecosystems.
Santen – Regional glaucoma device manufacturer
Expands implant manufacturing footprint and accelerates access to emerging Asia-Pacific hospitals.
Recent mergers and acquisitions are tightening competitive dynamics by concentrating key glaucoma surgery technologies in the hands of a few diversified ophthalmic device leaders. As these players bundle MIGS implants, phaco machines, and diagnostic platforms, hospital purchasing teams increasingly negotiate with portfolio suppliers rather than single-product vendors. This shift raises entry barriers for standalone device developers that lack the breadth to match bundled pricing and service contracts.
Market concentration is also influencing valuation multiples, with high-quality MIGS and digital surgery assets commanding premiums over broader medtech benchmarks. Buyers pay up for companies with late-stage clinical data, scalable manufacturing, and established reimbursement in major markets, reflecting expectations of sustained double-digit subsegment growth within an overall market growing at 7,40%. Conversely, early-stage platforms without reimbursement clarity see more disciplined pricing, as acquirers preserve capital for de‑risked opportunities.
Strategically, acquirers use M&A to reposition from product-centric to ecosystem-centric offerings. Owning both hardware and software around glaucoma surgery enables recurring revenue from service, upgrades, and data analytics, which supports higher enterprise valuations. Financial sponsors participate selectively, often backing roll-up strategies that combine smaller regional players into more competitive, multi-country platforms capable of partnering with large strategics or exiting via secondary sales.
Regionally, North America and Western Europe remain the most active hubs for glaucoma surgery acquisitions, driven by dense hospital networks, favorable reimbursement, and high adoption of minimally invasive procedures. Strategic buyers frequently acquire United States or European innovators and then leverage their commercial infrastructures to extend these solutions into Latin America and the Middle East.
In parallel, Asia-Pacific deal activity is rising as acquirers seek manufacturing efficiencies and regulatory-tailored devices for aging populations in Japan, China, and Southeast Asia. Across regions, transactions increasingly target technologies such as microstents, canaloplasty devices, smart implants, and surgical robotics, shaping the mergers and acquisitions outlook for Glaucoma Surgery Market and reinforcing a pipeline of data-rich, digitally integrated surgical platforms.
Competitive LandscapeRecent Strategic Developments
In January 2024, Alcon announced a strategic investment and distribution expansion by integrating a new minimally invasive glaucoma surgery (MIGS) implant into its global cataract portfolio. This move strengthened Alcon’s position in combination procedures, increased cross-selling opportunities with its intraocular lens business and intensified competitive pressure on smaller MIGS manufacturers that lack integrated surgical ecosystems.
In June 2023, Johnson & Johnson Vision completed an acquisition of a niche glaucoma device developer specializing in Schlemm’s canal-based stents. The acquisition type was a full buyout, and it enabled Johnson & Johnson Vision to broaden its glaucoma surgery pipeline, accelerate R&D synergies and challenge incumbent players in the MIGS segment by offering a more comprehensive refractive and glaucoma surgical suite.
In September 2023, Glaukos entered a strategic collaboration and licensing agreement with a diagnostic imaging company to pair its MIGS devices with advanced intraoperative visualization tools. This partnership created a differentiated value proposition focused on procedural guidance and outcomes tracking, prompting rival device manufacturers to explore similar technology tie-ups and raising the competitive bar for evidence-based glaucoma surgery solutions.
SWOT Analysis
-
Strengths:
The global glaucoma surgery market benefits from a strong clinical need for intraocular pressure reduction in patients who do not respond adequately to pharmacologic therapy or laser trabeculoplasty. A robust pipeline of minimally invasive glaucoma surgery devices, such as trabecular micro-bypass stents and subconjunctival implants, has expanded the range of interventional options and improved safety profiles compared with traditional trabeculectomy. The market is supported by established ophthalmic surgery infrastructure, including ambulatory surgery centers and integrated cataract–glaucoma procedure workflows. With the market projected by ReportMines to grow from USD 2,10 Billion in 2025 to USD 3,47 Billion in 2032 at a 7,40% CAGR, manufacturers benefit from predictable procedure volume growth, recurring revenue streams from implants and instrumentation, and strong relationships with ophthalmic surgeons who drive adoption of new surgical technologies.
-
Weaknesses:
The glaucoma surgery market faces structural weaknesses related to procedure complexity, heterogeneous patient selection and dependence on highly skilled glaucoma specialists. Adoption of novel devices remains uneven, as many ophthalmologists remain cautious about long-term efficacy compared with medical therapy, and some MIGS procedures have variable outcomes in advanced disease. Reimbursement constraints and coverage variability across payers and regions limit penetration in emerging markets and can slow hospital purchasing decisions for new implants and capital equipment. In addition, training requirements and steep learning curves for new surgical techniques constrain utilization rates, while high upfront costs for premium devices can deter smaller clinics and public hospitals, creating reliance on a limited set of high-volume surgical centers.
-
Opportunities:
The market offers significant opportunities in earlier-stage intervention, particularly through combined cataract and glaucoma surgery in aging populations with high cataract incidence. Device manufacturers can capitalize on the 7,40% CAGR by expanding portfolios into standalone MIGS procedures, suprachoroidal implants and microinvasive ab interno techniques that appeal to both comprehensive ophthalmologists and glaucoma subspecialists. There is substantial potential in emerging economies where rising diabetes prevalence and aging demographics are driving glaucoma incidence, creating demand for cost-effective surgical solutions. Integration of digital health tools, such as intraoperative imaging, surgical navigation and postoperative remote monitoring, opens opportunities for differentiated, outcome-driven offerings that can command premium pricing and foster long-term surgeon loyalty.
-
Threats:
The glaucoma surgery market is exposed to threats from rapid innovation cycles, competitive pricing pressure and evolving regulatory expectations for long-term safety and durability. Breakthroughs in sustained-release intraocular drug delivery or gene therapy could delay the need for surgical intervention in a significant portion of patients, reducing procedure volumes in some segments. Intensifying competition among large ophthalmic device companies and smaller innovators can trigger price erosion for implants and instruments, especially as payers scrutinize cost-effectiveness. Regulatory tightening, product recalls or unfavorable post-market surveillance data for specific device classes could undermine surgeon confidence and shift demand back toward medical therapy or alternative procedures, while macroeconomic pressures and healthcare budget constraints may delay capital investments in advanced glaucoma surgical technologies.
Future Outlook and Predictions
The global glaucoma surgery market is expected to follow a steady expansion trajectory over the next decade, anchored by consistent procedure growth and technology-driven value. Based on ReportMines data, the market is projected to increase from USD 2,10 Billion in 2025 to USD 3,47 Billion in 2032, reflecting a 7,40% CAGR and implying ongoing demand for interventional intraocular pressure control. This direction suggests that surgery will remain a core pillar of advanced glaucoma management rather than being displaced by pharmaceuticals, especially for patients with progression despite maximal medical therapy.
Technology evolution will be dominated by refinement of minimally invasive glaucoma surgery platforms and broader integration with cataract surgery workflows. Over the next 5–10 years, device portfolios are likely to shift from single-function stents toward modular systems that target multiple outflow pathways, such as Schlemm’s canal, the suprachoroidal space and subconjunctival drainage, within the same procedure. This progression will be driven by surgeon demand for predictable intraocular pressure reductions with lower complication rates than traditional trabeculectomy, as well as by payers rewarding shorter hospital stays and faster recovery.
Digital and imaging innovations will increasingly shape glaucoma surgery adoption and competitive differentiation. Advanced intraoperative optical coherence tomography, surgical guidance overlays and real-time intraocular pressure analytics are expected to become more common in high-volume ophthalmic centers. Vendors that embed software analytics, cloud-based outcome registries and remote device monitoring into their glaucoma surgery ecosystems will be better positioned to demonstrate durable efficacy and safety, enabling premium pricing and preferential inclusion in value-based care contracts.
Regulatory and reimbursement dynamics will remain a critical determinant of market direction. Authorities are likely to tighten post-market surveillance requirements for implants, emphasizing long-term safety, endothelial cell health and sustained intraocular pressure control beyond five years. However, positive health economic evidence demonstrating reduced visual disability and fewer revision surgeries should support broader reimbursement for combined cataract–glaucoma procedures, particularly in aging populations where cataract prevalence is high. Emerging markets will gradually expand reimbursement for cost-effective MIGS options, though adoption may lag due to budget constraints and limited specialist availability.
Competitive dynamics will intensify as large ophthalmic companies consolidate MIGS portfolios and smaller innovators pursue niche indications such as angle-closure glaucoma or secondary glaucomas. Over the next decade, partnerships between device manufacturers and pharmaceutical companies around sustained-release implants or hybrid surgical–drug platforms are likely to emerge, creating differentiated treatment algorithms. Players that combine robust clinical evidence, training programs for surgeons and scalable manufacturing will gain share, while those unable to prove long-term value may be pressured into licensing deals or exits.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Glaucoma Surgery Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for Glaucoma Surgery by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Glaucoma Surgery by Country/Region, 2017,2025 & 2032
- 2.2 Glaucoma Surgery Segment by Type
- Trabeculectomy instruments and consumables
- Glaucoma drainage devices and shunts
- Minimally invasive glaucoma surgery devices
- Laser-based glaucoma surgery systems
- Adjunctive surgical pharmaceuticals and viscoelastics
- 2.3 Glaucoma Surgery Sales by Type
- 2.3.1 Global Glaucoma Surgery Sales Market Share by Type (2017-2025)
- 2.3.2 Global Glaucoma Surgery Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global Glaucoma Surgery Sale Price by Type (2017-2025)
- 2.4 Glaucoma Surgery Segment by Application
- Primary open-angle glaucoma
- Angle-closure glaucoma
- Normal-tension glaucoma
- Secondary glaucoma
- Congenital and pediatric glaucoma
- 2.5 Glaucoma Surgery Sales by Application
- 2.5.1 Global Glaucoma Surgery Sale Market Share by Application (2020-2025)
- 2.5.2 Global Glaucoma Surgery Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global Glaucoma Surgery Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report